Progyny (PGNY) Q2 2026 Earnings Call Transcript
Progyny (PGNY) reported Q2 2026 revenue of $350.5M (+5.3% reported, +11% excluding a transition agreement), net income of $28.1M ($0.34/share), and adjusted EBITDA of $62.1M (17.7% margin). Fertility benefit revenue was $230.2M and pharmacy $120.3M. Guidance: 2026 revenue $1.36B-$1.385B and adjusted EBITDA $233M-$240M; Q3 revenue $335M-$345M.
How this was made
The 30-second read
Why it matters
The call combines a profitability upgrade (gross margin and adjusted EBITDA margin expansion) with forward guidance for both Q3 and full-year 2026, plus commentary on retention, renewals, and investment tapering into 2027.
Market read
Fresh earnings and guidance ranges, plus margin and growth metrics, create a tradable setup for PGNY into Q3 and for positioning around 2027 investment taper expectations.
What to watch
The guidance assumes a specific seasonal pattern and includes adjustments excluding a transition agreement; traders may need to separate underlying growth from one-off comparability effects.
Background
Progyny is a fertility benefits manager with revenue split between fertility and pharmacy benefit services, and it reports client and member growth alongside utilization (ART cycles).
Ticker impact
Progyny reported Q2 2026 revenue of $350.5M, raised 2026 guidance to $1.36B-$1.385B, and guided Q3 revenue to $335M-$345M.
Bias toward near-term upside as raised full-year revenue and EBITDA ranges offset seasonal Q3 caution.
The article provides multiple fresh, decision-relevant datapoints: Q2 results, full-year and Q3 guidance ranges, margin expansion, and a stated tapering of investment starting in 2027.
Market effects
Fertility benefits providers may see read-across on demand durability and margin drivers (care management efficiencies, platform investment taper).
No explicit regional impact beyond US employer-sponsored benefits demand.
Limited, as the business is tied to employer health plans and US market dynamics.
Counterpoint
Seasonality is flagged as the primary driver of sequential revenue change, so the market may discount Q3 guidance and focus on whether retention and utilization can sustain beyond summer.
Key entities
- companyProgyny
Reported Q2 2026 results and provided Q3 and full-year 2026 guidance, including margin expansion and client/member growth.
- executivePeter Anevski
CEO cited employer cost containment and medical need as drivers of selling momentum and discussed 2027 launch commitments.
- executiveMark S. Livingston
CFO highlighted seasonal member activity as the key assumption behind Q3 guidance and discussed margin expectations.
